Abstracts tagged "Biologics"

Abstract Number: 94 • 2014 ACR/ARHP Annual Meeting
Possible Effects of Medicare-Only Insurance Coverage on the Use of Biologics in Patients with RA
Marcia Genta, Dallas Arthritis Center, Dallas, TX
Background/Purpose: Biologics, a relatively new widely used class of medication that can substantially improve the course of RA, are expensive and their use is not…
Abstract Number: 2472 • 2014 ACR/ARHP Annual Meeting
The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression
Tatsuya Atsumi¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Osamu Togo¹¹, Toshiyuki Okada¹², Désirée M. van der Heijde¹³, Nobuyuki Miyasaka¹⁴ and Takao Koike^15,16, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Kitakyushu, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of orthopedics, Nagoya University Graduate School and Faculty of Medicine, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷Department of Rheumatology, Sasebo City General Hospital, Nagasaki, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, School of Medicine, Tohoku University, Tokyo, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Japan, ¹⁰Department of Clinical Research and Development, UCB Pharma, Tokyo, Japan, ¹¹Biometrics Group, UCB Pharma, Tokyo, Japan, ¹²Astellas Pharma Inc, Tokyo, Japan, ¹³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁴Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵NTT Sapporo Medical Center, Sapporo, Japan, ¹⁶Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose The efficacy and safety of certolizumab pegol (CZP)+methotrexate (MTX) therapy compared to MTX alone, in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with…
Abstract Number: 1556 • 2014 ACR/ARHP Annual Meeting
Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-up from the Psoriatic Arthritis Clinical Development Program
Arthur Kavanaugh¹, Iain B. McInnes², Christopher T. Ritchlin³, Proton Rahman⁴, Lluís Puig Sanz⁵, Alice B. Gottlieb⁶, Michael Song⁷, Bruce Randazzo⁷, Shu Li⁷, Yin You⁷ and Alan M. Mendelsohn⁸, ¹University of California San Diego, La Jolla, CA, ²University of Glasgow, Glasgow, United Kingdom, ³Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁴Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁵Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶Tufts Medical Center, Boston, MA, ⁷Janssen Research & Development, LLC., Spring House, PA, ⁸Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To report the safety of ustekinumab(UST) from the psoriatic arthritis (PsA)development program. Methods: Safety data through up to 2yrs of follow-up were pooled from…
Abstract Number: 1040 • 2014 ACR/ARHP Annual Meeting
Dysregulated Serum Interleukin 16 Concentration Associated with Clinical Disease Activity in Patients with Rheumatoid Arthritis Is Efficiently Corrected By Immunological Intervention
Atsuko Murota¹, Katsuya Suzuki¹, Yoshiaki Kassai², Takahiro Miyazaki³, Rimpei Morita⁴, Akihiko Yoshimura⁴ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Takeda Pharmaceutical Company, Fujisawa, Japan, ³Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ⁴Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: IL-16 is a chemoattractant factor that evokes massive infiltration of mononuclear cells in the synovial tissue in patients rheumatoid arthritis (RA). IL-16 concentrations are…
Abstract Number: 57 • 2014 ACR/ARHP Annual Meeting
Risk of Hospitalized Infection in a Psoriasis/Psoriatic Arthritis Cohort
Kevin L. Winthrop¹, Lang Chen², John Baddley², Allison Taylor³, Benjamin Chan⁴, Huifeng Yun⁵, Sarah Siegel⁶ and Jeffrey R. Curtis⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Oregon Health & Science University, Portland, OR, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriasis (PsO)/Psoriatic arthritis (PsA) often requires treatment with systemic immunosuppressive agents, some of which may increase hospitalized infection risk. Few population-based studies to date…
Abstract Number: 2467 • 2014 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab in Biologics NaÃ¯ve RA Patients – Interim Analysis of PMS for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-NaÃ¯ve RA Patients Study
Naoki Ishiguro¹, Tatsuya Atsumi², Masayoshi Harigai³, Tsuneyo Mimori⁴, Norihiro Nishimoto⁵, Takayuki Sumida⁶, Tsutomu Takeuchi⁷, Yoshiya Tanaka⁸, Nobuhiro Takagi⁹, Kunihiko Tanaka¹⁰ and Hisashi Yamanaka¹¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Medicine II School of Medicine, Hokkaido University, Sapporo, Japan, ³Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Rheum & Clinical Immunology, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ⁵Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka, Japan, ⁶Dept Internal Medicine, Univ of Tsukuba/Inst Clin Med, Tsukuba City, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁸First Dept of Internal Med, U Occupa & Environ Hlth, Kitakyushu, Japan, ⁹Medical Science, Chugai Pharmaceutical, Tokyo, Japan, ¹⁰Pharmacovigilance, Chugai Pharmaceutical, Tokyo, Japan, ¹¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The all-patient PMS study of tocilizumab (TCZ) followed 7901 RA patients for 28 wks. That study (hereafter, PMS7901) showed patients with a high probability…
Abstract Number: 1527 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison
Laura Sawyer¹, Stacey Chang¹, Alex Diamantopoulos² and Fred Dejonckheere³, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: To date, no head-to-head trials have been conducted comparing the efficacy of biologic treatments for early active rheumatoid arthritis (ERA). Here, we evaluated the…
Abstract Number: 941 • 2014 ACR/ARHP Annual Meeting
Biologic De-Escalation in Rheumatoid Arthritis: Cost Savings and Clinical Success
Tarun S. Sharma¹, Lyudmila Kirillova², Andrea Berger³ and Eric D. Newman⁴, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Rheumatology, Geisinger Health System, Danville, PA, ³Center for Health Research, Geisinger Health System, Danville, PA, ⁴Department of Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: Economic considerations and clinical risks of prolonged biologic use in Rheumatoid Arthritis (RA) have emerged as concerns. In this study, we measured the clinical…
Abstract Number: L2 • 2014 ACR/ARHP Annual Meeting
A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study
Petra C.E. Hissink Muller^1,2, D.M.C. Brinkman^1,3, Dieneke Schonenberg⁴, Yvonne Koopman-Keemink⁵, J. Merlijn Van den Berg⁶, W.P. Bekkering⁷, Marion van Rossum^8,9, Lisette WA van Suijlekom-Smit¹⁰, Cornelia F. Allaart¹¹ and Rebecca ten Cate¹, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pediatric Rheumatology, Reade, Amsterdam, Netherlands, ³Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, ⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁵Pediatrics, Haga ziekenhuis, The Hague, Netherlands, ⁶Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁷Pediatric Physiotherapy, Leiden University Medical Center, Leiden, Netherlands, ⁸Pediatric Rheumatology Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁹Reade, Amsterdam, Netherlands, ¹⁰Pediatric Rheumatology, Sophia Children's Hospital Erasmus Medical Center, Rotterdam, Netherlands, ¹¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: BeSt for Kids compares 3 Disease Modifying Anti Rheumatic Drug (DMARD) strategies in juvenile idiopathic arthritis (JIA) patients, for time to inactive disease, time…
Abstract Number: 2397 • 2014 ACR/ARHP Annual Meeting
Improvement of Fatigue in Patients with Rheumatoid Arthritis Treated with Biologics: Relationship with Sleep Disorders, Depression and Clinical Efficacy. a Prospective, Multicenter Study
Marlène Genty¹, Marie Kostine², Elodie Ardouin³, Bernard Combe⁴ and Cédric Lukas⁵, ¹RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France, ²Rheumatology, CHU Pellegrin, Bordeaux, France, ³Rheumatology, Limoges University Hospital, Limoges, France, ⁴Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁵Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France
Background/Purpose The functional burden of disease in Rheumatoid arthritis (RA) patients, mainly caused by inflamed joints, is often worsened by extra-articular manifestations, among which asthenia remains…
Abstract Number: 1525 • 2014 ACR/ARHP Annual Meeting
Cumulative Clinical Â Response in Â RheumatoidÂ Arthritis Patients with Â Rituximab Repeated Courses after Failure to TumorÂ Necrosis Factor Inhibitors in RoutineÂ Clinical Practice Â
Catalin Codreanu¹, Ruxandra Ionescu², Ioan Ancuta³, Corina Mogosan⁴, Simona Rednic⁵, Paulina Ciurea⁶, Maria Suta⁷, Magda Parvu⁸, Andra Balanescu², Mihai Bojinca³, Dan Nemes⁹, Codrina Ancuta¹⁰ and Elena Rezus¹¹, ¹5 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ²Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ³Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, ⁴'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ⁵Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania, ⁶Clinical County Hospital,Craiova, Craiova, Romania, ⁷317 Tomis Str. , Bl. 4A, ap. 3, Constanta Municipal Hospital, Constanta, Romania, ⁸Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, ⁹Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ¹⁰G.T.Popa Center for Biomedical Research, Iasi, Romania, ¹¹Rheumatology, Recovering Clinical Hospital, Iasi, Romania
Background/Purpose The concept of achieving tight control of rheumatoid arthritis (RA) and treating to target has been well established. It focuses on early diagnosis, aggressive…
Abstract Number: 933 • 2014 ACR/ARHP Annual Meeting
A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients with Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results
Hermine I. Brunner¹, Nicolino Ruperto², N Tzaribachev³, Gerd Horneff⁴, Carine Wouters⁵, Violeta Vladislava Panaviene⁶, Vyacheslav Chasnyk⁷, Carlos Abud-Mendoza⁸, Ruben Cuttica⁹, Andreas Reiff¹⁰, M Maldonado-Velázquez¹, Nadina Rubio-Pérez¹¹, Rik Joos¹², V Keltsev¹³, Evgeny Nasonov¹⁴, Daniel Kingsbury¹⁵, M Bandeira¹⁶, Earl Silverman¹⁷, F Weller-Heinemann¹¹, A van Royen-Kerkhof¹⁸, Alan M. Mendelsohn¹⁹, Lilianne Kim²⁰, Daniel Lovell²¹ and A Martini²², ¹PRCSG, Cincinnati, OH, ²Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ³PRINTO & PRCSG, Bramstedt, Germany, ⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁵Pediatric Rheumatology, University Hosp Gasthuisberg, Leuven, Belgium, ⁶Istituto Giannina Gaslini, Genoa, Italy, ⁷Litovskaya Str., 2, Novartis Pharma, Saint-Peterburg, Russia, ⁸Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁹Tilcara 3023, Hospital de Ninos Pedro de Elizalde, Capital Federal, Argentina, ¹⁰Children’s Hospital of Los Angeles, Los Angeles, CA, ¹¹PRINTO, Genoa, Italy, ¹²UZ Gent, Gent, Belgium, ¹³Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genoa, Italy, ¹⁴State Institute of Rheumatology of RAMS, Moscow, Russia, ¹⁵Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹⁶Pediatrics, Hospital Infantil Pequeno Príncipe, Curitiba, Brazil, ¹⁷Division of Rheumatology, Hosp for Sick Children, Toronto, ON, Canada, ¹⁸Department of Pediatric Immunology & Rheumatology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Immunology, Janssen Research & Development, LLC., Spring House, PA, ²⁰Janssen Research & Development, LLC., Spring House, PA, ²¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ²²Istituto Gaslini-PRINTO, Genova, Italy
Background/Purpose: To assess efficacy and safety of SC golimumab (GLM) in polyarticular pediatric juvenile idiopathic arthritis pts (aged 2 to
Abstract Number: 2325 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy
Josef S. Smolen¹, Jonathan Kay², Robert Landewé³, Eric L. Matteson⁴, Norman B. Gaylis⁵, Jürgen Wollenhaupt⁶, Frederick T. Murphy⁷, Chenglong Han⁸, Timothy A. Gathany⁸, Stephen Xu⁹, Yiying Zhou¹⁰, Elizabeth C. Hsia⁹ and Mittie K. Doyle⁹, ¹Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, ³Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁶Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁷Altoona Ctr for Clinical Research, Duncansville, PA, ⁸Janssen Global Services, LLC., Malvern, PA, ⁹Janssen Research & Development, LLC., Spring House, PA, ¹⁰Biostatistics, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: GO-AFTER was the first multicenter, randomized, placebo (PBO)-controlled trial of the safety/efficacy of an anti-TNFα agent, GLM, in pts with active RA despite prior…
Abstract Number: 1534 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody Injected Subcutaneously Every 4 Weeks, In Chinese Patients With Active Ankylosing Spondylitis: 1-Year Results Of a Phase 3, Randomized, Placebo-Controlled Study
Chunde Bao¹, Feng Huang², Muhammad Asim Khan³, Kaiyin Fei⁴, Zhong Wu⁴, Yanli Zhuang⁴, Timothy A. Gathany⁵, Chenglong Han⁵ and Elizabeth C. Hsia⁴, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Dept of Rheumatology, Chinese PLA General Hospital, Beijing, China, ³Medicine/ Rheumatology, Case Western Reserve University Hospital, Cleveland, OH, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Janssen Global Services, LLC., Malvern, PA
Background/Purpose: A multicenter, randomized, placebo (PBO)-controlled study of golimumab (GLM) was performed in Chinese pts with ankylosing spondylitis (AS). To assess efficacy and safety of…
Abstract Number: 800 • 2013 ACR/ARHP Annual Meeting
A Strategy For Selecting Individuals With RA For Reduction Of Anti-TNF Therapy Using Combined Clinical and Ultrasound Assessment
Christopher R. Holroyd^1,2, Brian Davidson³, Sarah Bennett³, David Waghorn³, Caron Underhil³, Cyrus Cooper², Antonia Calogeras³, Elaine M. Dennison⁴, Nicholas C. Harvey⁵, Ray Armstrong³, Stephan Gadola⁶ and Christopher J. Edwards^7,8, ¹Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ²MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ³University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁵University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ⁶University of Southampton, Southampton, United Kingdom, ⁷NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ⁸University of Southampton, Southampton, United Kingdom
Background/Purpose: Reducing the dose of biological therapy may be possible for patients with rheumatoid arthritis (RA) who have achieved remission or low disease activity (LDA). …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].